About Novoron Bioscience
Novoron Bioscience is a Healthcare company based in San Diego (United States) founded in 2013. Therapeutics for neurological diseases and CNS nerve regeneration are developed. Novoron Bioscience has raised $15.13 million across 12 funding rounds from investors including HHS, National Institute on Aging and Two Bear Capital. The company has 13 employees. Novoron Bioscience offers products and services including Small Molecule Therapies and Neuroregeneration Therapies. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is NOVORON BIOSCIENCE, INC. Its competitors include Sana Biotechnology, Kriya Therapeutics and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Novoron Bioscience was founded in 2013 and is based in San Diego, United States. Operations focus on the biotechnology sector, where therapeutics for neurological diseases are developed. Emphasis is placed on nerve regeneration in the central nervous system, particularly for spinal cord injuries. Biologic therapeutics are provided to inhibit the LRP1Rho pathway, supporting neuronal and axonal regeneration.
- Headquarters San Diego, United States
- Employees 13
- SectorsHealthcare
- Website novoron.com
- Social LinkedIn X Facebook
- Legal Name Novoron Bioscience, Inc.
- Total Equity Funding$15.13M (USD)
in 12 rounds
- InvestorsHHS
& 5 more
- Employee Count13
Products & Services of Novoron Bioscience
Novoron Bioscience offers a comprehensive portfolio of products and services, including Small Molecule Therapies and Neuroregeneration Therapies.
Therapies to block prion-like proteins and prevent neurodegeneration.
Enhances spinal cord regenerative capacity after traumatic injury.
Funding Insights of Novoron Bioscience
Novoron Bioscience has successfully raised a total of $15.13M across 12 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.13M
- Total Rounds 12
- First Round $330,056
(Jul 2014)
- Investors Count 6
Latest 10 of 12 funding rounds of Novoron Bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | Seed | – | – | ||
| Dec 2022 | $12.13M | Series A | – | – | – |
| Jan 2022 | Grant | – | – | ||
| Nov 2021 | $3M | Seed | – | Two Bear Capital | – |
| Sep 2021 | $844,655 | Grant | – | – | |
| Sep 2019 | $707,181 | Grant | – | – | |
| Apr 2018 | $695,052 | Grant | – | – | |
| Mar 2018 | Seed | – | – | ||
| Dec 2015 | $680,000 | Grant | – | – | |
| Sep 2015 | $673,853 | Grant | – | – |
6 investors in total: 6 institutional.
Investors in Novoron Bioscience
Novoron Bioscience has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, National Institute on Aging and Two Bear Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Two Bear Capital is focused on investing in innovative founders. | 2019 | twobearcapital.com | Whitefish, Montana, USA | |
| backstagecapital.com | ||||
| sbir.nih.gov | ||||
Research and information on aging are provided by this institute. | nia.nih.gov | Bethesda, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
| bija.vc |
Investor details for Novoron Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Novoron Bioscience
10 people are tracked at Novoron Bioscience (4 in leadership, 4 in board & advisors, 2 in team); the tracked headcount is 13.
| Name | Role | Group |
|---|---|---|
Travis Stiles | CEO & CSO | Leadership |
Shawn Gahr | COO & CFO | Leadership |
A. Taylor Bright | Co-Founder and Chief Operating Officer | Leadership |
Lisa Ortega | Executive Assistant To Chief Executive Officer | Leadership |
Miguel de los Rios | Business Advisor | Board & advisors |
Rivka Kreitman | Business Advisor | Board & advisors |
Revere Kinkel | Scientific Advisor | Board & advisors |
Robert Eastlack | Scientific Advisor | Board & advisors |
Tom Gawriluk, Ph.D. | Spinal Cord Injury Project Lead | Team |
Ryan Fischer | Lab Operations & Assay Development Manager | Team |
Complete people profiles for Novoron Bioscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Novoron Bioscience
3 dated milestones of Novoron Bioscience across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Novoron Bioscience is founded.
- Funding First funding round of $330K.
- Funding Latest funding round, Seed,.
Competitors of Novoron Bioscience
Novoron Bioscience has 3 listed competitors in our database, 3 of them funded. They include Sana Biotechnology, Kriya Therapeutics and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Novoron Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Novoron Bioscience
The website of Novoron Bioscience (novoron.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 7.3% vs previous month
Websites whose visitors overlap most with Novoron Bioscience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ventrixbio.com | 100% | 1.8K | #8,229,176 | View details | |
| abdesignlabs.com | 100% | 4.7K | #4,128,811 | View details | |
| nanome.ai | 99% | 3.9K | #4,650,815 | View details | |
| gribio.com | 98% | 3.1K | #5,745,404 | View details | |
| curemetrix.com | 97% | 2.7K | #5,895,624 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Novoron Bioscience
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Novoron Bioscience (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novoron Bioscience
Complete news archive for Novoron Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novoron Bioscience
Novoron Bioscience was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Novoron Bioscience is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Novoron Bioscience is a funded company, having raised a total of $15.13M across 12 funding rounds to date. The company's 1st funding round was a Grant of $673.85K, raised on Jul 2014.
Novoron Bioscience has 13 employees.
Novoron Bioscience was founded in 2013 and is based in San Diego, United States. Operations focus on the biotechnology sector, where therapeutics for neurological diseases are developed. Emphasis is placed on nerve regeneration in the central nervous system, particularly for spinal cord injuries. Biologic therapeutics are provided to inhibit the LRP1Rho pathway, supporting neuronal and axonal regeneration.
Novoron Bioscience's top competitors include Sana Biotechnology, PureTech Health and Kriya Therapeutics.
Novoron Bioscience offers Small Molecule Therapies and Neuroregeneration Therapies.
Novoron Bioscience has 6 investors. Key investors include HHS, National Institute on Aging, Two Bear Capital, Backstage Capital, and NIH SBIR/STTR.
Novoron Bioscience operates through Novoron Bioscience, Inc..